Amirreza Ghayeghran * 1,
Elaheh Ghahramani1 ,
Alia Saberi1 ,
Hamidreza Hatamian1 ,
Enayattollah Homaie Rad2 ,
Samaneh Ghorbani Shirkouhi3 ,
Rita Khayami1 ,
Mehri Fallahi4 ,
Fatemeh Shafaei5 ,
Parisa Shahshahani1 ,
Zoheir Reihanian6
1- Neuroscience Research Center, Department of Neurology, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran
2- Social Determinants of Health Research Center, Guilan University of Medical Sciences, Rasht, Iran
3- Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran
4- Guilan MS Association, Rasht, Iran
5- Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran
6- Department of Neurosurgery, School of Medicine, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran
Abstract: (778 Views)
Background: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system. COVID-19 has presented a significant challenge to the care providers of patients with MS.
Objectives: The present study aimed to investigate the frequency of COVID-19 infection and its seropositivity in MS patients in Guilan, Iran, in 2021.
Materials & Methods: In this analytical-cross-sectional study, all patients with relapsing-remitting MS registered in the Guilan MS Association with an expanded disability status scale of less than 5 who were referred for evaluation participated in the study. Information related to the clinical and serological symptoms of COVID-19 infection, changes in drug use, and the occurrence of new attacks were collected. Serological results of COVID-19 (IgG) among them were registered.
Results: In total, 260 patients with MS (78.8% women, and 21.2% men) with a Mean±SD age of 38.7±9.9 years, and a Mean±SD duration of MS of 8.9±4.9 years were investigated. The most commonly used drugs were Dimethyl fumarate, Interferon, and Rituximab, respectively. Thirty-three patients (12.6%) had a clinical COVID-19 infection, of which 32 people had a mild and only one had a critical infection. Eight patients (1.3%) had positive COVID-19 IgG tests. No significant relationship was found between the COVID-19 infection with the type of medication, medication change, clinical attack of MS, and co-morbidities (P>0.05).
Conclusion: A few patients had positive COVID-19 IgG tests and clinical COVID-19 infection. The vast majority had mild disease, and the clinical attack was not related to COVID-19 infection.
Full-Text [PDF 1693 kb]
(461 Downloads)
| |
Full-Text (HTML) (523 Views)
• COVID-19 could provoke the immune system or multiple sclerosis (MS) to predispose patients more to
COVID-19 infection.
• But a few patients had positive COVID-19 IgG tests and clinical COVID-19 infection.
• The vast majority of patients with MS and COVID-19 had mild disease, and the clinical attack was not related
to COVID-19 infection.
Type of Study:
Research |
Subject:
Special Received: 2022/12/17 | Accepted: 2023/01/11 | Published: 2023/01/11